CHINA HONGBAO (08316) signs debt waiver agreement with executive director Cheng Jun
China Red Envelope (08316) announced that on March 27, 2026, Mr. Cheng Jun, an executive director and shareholder of the company holding approximately 18.89% of the issued shares, signed a debt waiver agreement. According to the debt waiver agreement, Mr. Cheng Jun irrevocably and unconditionally waives the company's total debt to him of approximately HK$20.1 million (including principal and accrued interest).
CHINA HONGBAO (08316) announces that on March 27, 2026, the company and Executive Director and shareholder Mr. Cheng Jun, who holds approximately 18.89% of the issued shares of the company, signed a debt waiver agreement. According to the debt waiver agreement, Mr. Cheng Jun irrevocably and unconditionally waives the company's total debt of approximately HKD 20.1 million (including principal and related accrued interest, if any).
The Board believes that signing the debt waiver agreement is in the overall interest of the company and all its shareholders, and will help improve the Group's financial position.
Related Articles

CHI PEOPLE HOLD (00681) issued a profit warning, expecting to incur a loss of approximately 143 million yuan in 2025, a turnaround from a profit in the previous year.

NEWLINK TECH (09600) announced its performance in 2025, with a net loss attributable to owners of approximately 188 million yuan, a year-on-year increase of 103.26%.

BYD Company (01211) released its annual performance, with a net profit attributable to shareholders of 32.619 billion yuan. Research and development investment increased by 17% to 63.4 billion yuan compared to the previous year.
CHI PEOPLE HOLD (00681) issued a profit warning, expecting to incur a loss of approximately 143 million yuan in 2025, a turnaround from a profit in the previous year.

NEWLINK TECH (09600) announced its performance in 2025, with a net loss attributable to owners of approximately 188 million yuan, a year-on-year increase of 103.26%.

BYD Company (01211) released its annual performance, with a net profit attributable to shareholders of 32.619 billion yuan. Research and development investment increased by 17% to 63.4 billion yuan compared to the previous year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


